Seven Fleet Capital Management LP Takes $855,000 Position in Alkermes plc $ALKS

Seven Fleet Capital Management LP acquired a new position in shares of Alkermes plc (NASDAQ:ALKS) in the first quarter, HoldingsChannel reports. The fund acquired 24,170 shares of the company’s stock, valued at approximately $855,000.

Several other large investors have also made changes to their positions in the company. Cullen Frost Bankers Inc. acquired a new position in Alkermes in the fourth quarter valued at $28,000. Johnson Financial Group Inc. acquired a new stake in Alkermes during the third quarter worth about $31,000. UMB Bank n.a. raised its holdings in shares of Alkermes by 57.6% in the 4th quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock worth $34,000 after purchasing an additional 446 shares during the period. Salomon & Ludwin LLC raised its holdings in shares of Alkermes by 115.6% in the 4th quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company’s stock worth $35,000 after purchasing an additional 667 shares during the period. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in shares of Alkermes by 1,041.4% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,324 shares of the company’s stock valued at $37,000 after purchasing an additional 1,208 shares in the last quarter. 95.21% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on ALKS shares. Royal Bank Of Canada boosted their target price on Alkermes from $45.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, June 9th. Piper Sandler restated an “overweight” rating and issued a $65.00 price target (up from $43.00) on shares of Alkermes in a report on Tuesday. Wells Fargo & Company lifted their price target on shares of Alkermes from $44.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, June 29th. UBS Group boosted their price objective on shares of Alkermes from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Robert W. Baird increased their price objective on shares of Alkermes from $48.00 to $58.00 and gave the stock an “outperform” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Alkermes has a consensus rating of “Moderate Buy” and an average price target of $54.56.

Alkermes News Roundup

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Wells Fargo issued a Buy rating on Alkermes, providing a favorable view of the company’s outlook and potentially supporting investor confidence. Wells Fargo Gives a Buy Rating to Alkermes
• Positive Sentiment: JPMorgan raised its price target to $61, while Robert W. Baird reportedly expects the shares to rise. The targets indicate that some analysts see additional upside from current levels. JPMorgan Raises Alkermes Price Target Baird Analyst Expects Alkermes Stock to Rise
• Neutral Sentiment: Analyst opinions remain mixed, with Wells Fargo’s Buy stance contrasting with HC Wainwright’s Neutral rating. Alkermes also released its second-quarter 2026 earnings-call presentation, giving investors additional information to assess operating performance and its pipeline. Mixed Analyst Opinions on Alkermes Alkermes 2026 Second-Quarter Earnings Presentation
• Negative Sentiment: HC Wainwright significantly lowered its earnings outlook across multiple periods. Its Q3 2026 EPS estimate moved to a loss of $0.09 from a profit of $0.03, while its FY2026 estimate fell to a loss of $0.71 from a loss of $0.44. Forecasts also declined for FY2027 through FY2030, including FY2028 moving to a loss of $0.29 from earnings of $0.52 and FY2029 falling to $0.55 from $1.27. The firm maintained a Neutral rating, signaling weaker expected profitability and a more cautious long-term view.

Alkermes Trading Down 2.1%

Shares of ALKS opened at $48.99 on Friday. The stock’s 50-day moving average is $48.24 and its two-hundred day moving average is $38.17. The stock has a market cap of $8.22 billion, a PE ratio of 128.92 and a beta of 0.34. Alkermes plc has a 12 month low of $25.17 and a 12 month high of $55.67. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.30 and a quick ratio of 1.70.

Insider Activity

In related news, EVP Craig C. Hopkinson sold 9,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $51.51, for a total transaction of $463,590.00. Following the sale, the executive vice president directly owned 73,389 shares in the company, valued at approximately $3,780,267.39. This trade represents a 10.92% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Joseph Gaffin sold 2,034 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $54.03, for a total value of $109,897.02. Following the transaction, the executive vice president directly owned 227,490 shares in the company, valued at $12,291,284.70. This trade represents a 0.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 26,102 shares of company stock worth $1,193,810. 4.59% of the stock is currently owned by corporate insiders.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.